Serum androgen levels have been shown to be prognostic for overall survival in 1,195 patients with metastatic castration-resistant prostate cancer in a phase III study of abiraterone acetate plus prednisone versus prednisone alone. A baseline serum androgen level above median (median levels of testosterone, androstenedione, and dehydroepiandrosterone sulfate were 5.0 ng/dL, 23.7 ng/dL, and 16 μg/dL, respectively) was associated with longer survival in both treatments arms.
ORIGINAL RESEARCH PAPER
Ryan, C. J. et al. Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. J. Clin. Oncol. 10.1200/JCO.2012.45.4595
Rights and permissions
About this article
Cite this article
Serum androgens levels are prognostic in prostate cancer. Nat Rev Clin Oncol 10, 486 (2013). https://doi.org/10.1038/nrclinonc.2013.128
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2013.128